By Dominique Patton PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% ...

Resideo Technologies (REZI) has disclosed a new risk, in the Share Price & Shareholder Rights category. The CD&R Stockholder, holding approximately 11% of Resideo Technologies’ total voting power as ...

Sanofi entered into exclusive talks to sell a controlling stake in its consumer-healthcare business Opella to Clayton ...

In September, Bloomberg reported that Sanofi had received two separate bids from CD&R and rival PAI Partners for the Opella unit. CD&R has kept away interest from rival PAI Partners for the unit ...

The renewed negotiations come after CD&R agreed to pledges around local jobs, investments and production, Bloomberg reported earlier. Sanofi encountered a backlash in France when it chose the US ...

CD&R is also considering the French government’s request to keep the consumer health unit’s headquarters in France, said the people, who asked not to be identified as the information is private.

Clayton Dubilier & Rice is nearing a deal to acquire Sanofi’s consumer health unit for about €15 billion ($16.4 billion), in what would be one of the largest European transactions this year ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcareSanofi and CD&R enter exclusive negotiations to transfer a 50% ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

The French finance ministry said in a statement that CD&R was a "serious investment fund" with positive prospects for Opella's development and its plants in France. It added that it would require ...

(Reuters) -Sanofi is closing in on a deal to sell its consumer health unit for about 15 billion euros ($16.4 billion) to U.S. private equity firm Clayton Dubilier & Rice (CD&R), a person familiar ...

The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...